Amber Freeman
Family · Dothan, ALNPI 1780218123
Payments from drug & device makers
Across 312 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$820
- Lilly USA, LLC$809
- AstraZeneca$527
- Dexcom, Inc.$481
- GSK$329
- AbbVie$324
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,931100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $820 |
| Lilly USA, LLC | 61 | $809 |
| AstraZeneca | 27 | $527 |
| Dexcom, Inc. | 37 | $481 |
| GSK | 20 | $329 |
| AbbVie | 18 | $324 |
| Pfizer | 11 | $212 |
| Boehringer Ingelheim | 11 | $186 |
| Merck | 10 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $110 |
| Exact Sciences | 6 | $108 |
| Amarin Pharma, Inc. | 5 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Bayer | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Amgen | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Johnson & Johnson | 3 | $55 |
| Corcept Therapeutics | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Baxter Healthcare | 1 | $45 |
| Eisai Inc. | 3 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Corium, LLC | 1 | $25 |
| IBSA Pharma Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $12 |
How this compares
$4,931 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 104 | $138,682 |
| OzempicSemaglutide | 103 | $106,252 |
| EliquisApixaban | 49 | $53,246 |
| JardianceEmpagliflozin | 42 | $35,043 |
| TrulicityDulaglutide | 26 | $31,189 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $31,055 |
| WegovySemaglutide | 13 | $25,518 |
| FarxigaDapagliflozin Propanediol | 28 | $23,290 |
| XareltoRivaroxaban | 12 | $21,417 |
| VascepaIcosapent Ethyl | 23 | $10,576 |
| MyrbetriqMirabegron | 14 | $9,582 |
| MultaqDronedarone Hcl | 11 | $8,830 |
| LinzessLinaclotide | 12 | $8,211 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $7,231 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 12 | $5,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $809 | $169,871130 claims |
| Novo NordiskOzempic, Wegovy | $820 | $131,770116 claims |
| PfizerEliquis | $212 | $53,24649 claims |
| Boehringer IngelheimJardiance | $186 | $35,04342 claims |
| GSKTrelegy Ellipta | $329 | $31,05537 claims |
| AstraZenecaFarxiga | $527 | $23,29028 claims |
| Johnson & JohnsonXarelto | $55 | $21,41712 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $9,58214 claims |
| AbbVieLinzess | $324 | $8,21112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Dothan
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.